Cargando…

Anti-SARS-CoV-2 Antibodies Within IVIg Preparations: Cross-Reactivities With Seasonal Coronaviruses, Natural Autoimmunity, and Therapeutic Implications

Introduction: Cross-reactivity to SARS-CoV-2 antigenic peptides has been detected on T-cells from pre-pandemic donors due to recognition of conserved protein fragments within members of the coronavirus's family. Further, preexisting antibodies recognizing SARS-CoV-2 with conserved epitopes in t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dalakas, Marinos C., Bitzogli, Kleopatra, Alexopoulos, Harry
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7925824/ https://www.ncbi.nlm.nih.gov/pubmed/33679770 http://dx.doi.org/10.3389/fimmu.2021.627285

Ejemplares similares

Anti–SARS-CoV-2 antibodies in the CSF, blood-brain barrier dysfunction, and neurological outcome: Studies in 8 stuporous and comatose patients
por: Alexopoulos, Harry, et al.
Publicado: (2020)

Anti-SARS-CoV-2 antibody detection in healthcare workers of two tertiary hospitals in Athens, Greece
por: Vlachoyiannopoulos, Panayiotis, et al.
Publicado: (2020)

Update on Intravenous Immunoglobulin in Neurology: Modulating Neuro-autoimmunity, Evolving Factors on Efficacy and Dosing and Challenges on Stopping Chronic IVIg Therapy
por: Dalakas, Marinos C.
Publicado: (2021)

Long-term Effectiveness of IVIg Maintenance Therapy in 36 Patients With GAD Antibody–Positive Stiff-Person Syndrome
por: Yi, Jessica, et al.
Publicado: (2022)

IgG4-Mediated Neurologic Autoimmunities: Understanding the Pathogenicity of IgG4, Ineffectiveness of IVIg, and Long-Lasting Benefits of Anti–B Cell Therapies
por: Dalakas, Marinos C.
Publicado: (2021)

Autoimmune encephalitis with GABA(B) antibodies, thymoma, and GABA(B) receptor thymic expression
por: Alexopoulos, Harry, et al.
Publicado: (2014)

Quantitative clinical and autoimmune assessments in stiff person syndrome: evidence for a progressive disorder
por: Rakocevic, Goran, et al.
Publicado: (2019)

GAD antibody-spectrum disorders: progress in clinical phenotypes, immunopathogenesis and therapeutic interventions
por: Tsiortou, Popianna, et al.
Publicado: (2021)

The importance of FcRn in neuro-immunotherapies: From IgG catabolism, FCGRT gene polymorphisms, IVIg dosing and efficiency to specific FcRn inhibitors
por: Dalakas, Marinos C., et al.
Publicado: (2021)

Autoimmune Neurological Disorders with IgG4 Antibodies: a Distinct Disease Spectrum with Unique IgG4 Functions Responding to Anti-B Cell Therapies
por: Dalakas, Marinos C.
Publicado: (2022)

Autoimmune Neurogenic Dysphagia
por: Stathopoulos, Panos, et al.
Publicado: (2021)

Anti-MOG antibodies are frequently associated with steroid-sensitive recurrent optic neuritis
por: Chalmoukou, Konstantina, et al.
Publicado: (2015)

Evolution of Anti-B Cell Therapeutics in Autoimmune Neurological Diseases
por: Stathopoulos, Panos, et al.
Publicado: (2022)

Stiff-person Syndrome and GAD Antibody-spectrum Disorders: GABAergic Neuronal Excitability, Immunopathogenesis and Update on Antibody Therapies
por: Dalakas, Marinos C.
Publicado: (2022)

Complement in neurological disorders and emerging complement-targeted therapeutics
por: Dalakas, Marinos C., et al.
Publicado: (2020)

Guillain-Barré syndrome: The first documented COVID-19–triggered autoimmune neurologic disease: More to come with myositis in the offing
por: Dalakas, Marinos C.
Publicado: (2020)

Advances in the diagnosis, immunopathogenesis and therapies of IgM-anti-MAG antibody-mediated neuropathies
por: Dalakas, Marinos C.
Publicado: (2018)

Intravenous Immunoglobulins: Evolution of Commercial IVIG Preparations
por: Hooper, John A.
Publicado: (2008)

Therapeutic Antibodies in Neurological Diseases: Witnessing the Continuation of the Impressive Success in Neuro-Immunotherapies
por: Dalakas, Marinos C., et al.
Publicado: (2022)

Repurposing MS immunotherapies for CIDP and other autoimmune neuropathies: unfulfilled promise or efficient strategy?
por: Kohle, Felix, et al.
Publicado: (2023)

Inflammatory myopathies: update on diagnosis, pathogenesis and therapies, and COVID-19-related implications
por: Dalakas, Marinos C.
Publicado: (2020)

Antibodies to inositol 1,4,5-triphosphate receptor 1 in patients with cerebellar disease
por: Fouka, Penelope, et al.
Publicado: (2016)

Antibody Responses after SARS-CoV-2 Vaccination in Patients with Liver Diseases
por: Bakasis, Athanasios-Dimitrios, et al.
Publicado: (2022)

Overnight loss of pigmented hair in autoimmune autonomic neuropathy treated with IVIg
por: Turner, Lindsey E., et al.
Publicado: (2019)

IVIg for apparently autoimmune small-fiber polyneuropathy: first analysis of efficacy and safety
por: Liu, Xiaolei, et al.
Publicado: (2018)

Aggressive Herpes Zoster in Young Patients With Multiple Sclerosis Under Dimethyl Fumarate: Significance of CD8(+) and Natural Killer Cells
por: Anagnostouli, Maria C., et al.
Publicado: (2021)

Antibody diversity in IVIG: Therapeutic opportunities for novel immunotherapeutic drugs
por: von Gunten, Stephan, et al.
Publicado: (2023)

Neurological complications of immune checkpoint inhibitors: what happens when you ‘take the brakes off’ the immune system
por: Dalakas, Marinos C.
Publicado: (2018)

Gene therapy for Duchenne muscular dystrophy: balancing good science, marginal efficacy, high emotions and excessive cost
por: Dalakas, Marinos C.
Publicado: (2017)

Therapies in Stiff-Person Syndrome: Advances and Future Prospects Based on Disease Pathophysiology
por: Dalakas, Marinos C.
Publicado: (2023)

Objectivity, practicality, and significance of practice guidelines for the practicing neurologists: What we learnt from consensus criteria in CIDP, Myasthenia Gravis and Inflammatory Myopathies
por: Dalakas, Marinos C.
Publicado: (2023)

Postherpes simplex encephalitis: a case series of viral-triggered autoimmunity, synaptic autoantibodies and response to therapy
por: Alexopoulos, Harry, et al.
Publicado: (2018)

Treatment of scleromyxedema with IVIg
por: Moser, David W, et al.
Publicado: (2012)

Methylprednisolone Pulse Therapy or Additional IVIG for Patients with IVIG-Resistant Kawasaki Disease
por: Wang, Zhouping, et al.
Publicado: (2020)

Prediction of Peptide Reactivity with Human IVIg through a Knowledge-Based Approach
por: Barbarini, Nicola, et al.
Publicado: (2011)

Cost-minimisation analysis of plasma exchange versus IVIg in the treatment of autoimmune neurological conditions
por: Klemencic Kozul, Tara, et al.
Publicado: (2022)

IVIg Treatment Reduces Catalytic Antibody Titers of Renal Transplanted Patients
por: Mahendra, Ankit, et al.
Publicado: (2013)

A Comparative Study of IVIG versus IVIG with IV Methylprednisolone in Guillain–Barre Syndrome
por: Bhattiprolu, Rahi Kiran, et al.
Publicado: (2020)

Late and booster anti‐SARS‐CoV‐2 humoral responses in nonresponder vaccinated patients with rheumatic diseases receiving mycophenolate or rituximab: comment on the article by XXX et al
por: Bakasis, Athanasios‐Dimitrios, et al.
Publicado: (2022)

Correction: Prediction of Peptide Reactivity with Human IVIg through a Knowledge-Based Approach
por: Barbarini, Nicola, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_fsouedsl1hb254qr26rlrulc6r